The FDA approved Lembaz on Tuesday to reduce the risk of death in adults and children with infantile-onset Niemann-Pick disease type C, a rare inherited disorder that progressively damages the nervous system.
The approval covers patients who weigh at least 7 kilograms, about 15 pounds, and whose neurological symptoms began before age 6. That threshold concerns when symptoms started. An adult can qualify if the symptoms began in early childhood.
Lembaz, also called adrabetadex, is the first NPC treatment shown to improve survival in this group, according to the FDA's announcement. Two earlier approved therapies had not demonstrated a reduction in the risk of death.
Beren Therapeutics says commercial treatment sites nationwide will begin offering Lembaz in early December. The company owns Mandos, which received the approval.
What the survival evidence shows
The FDA assessed 36 treated patients across three clinical studies and an expanded access program. All had developed neurological symptoms before age 6. Their survival was compared with a matched external control group.
The agency reported a 55% lower risk of death in the treated group. This was a comparison with patients outside the treated studies, rather than a survival comparison between two randomly assigned groups. The result describes the studied group; it does not predict how long an individual patient will live.
NPC prevents cells from properly processing cholesterol and other fats. Their accumulation can impair movement, coordination and swallowing.
Hearing monitoring is part of treatment

The prescribing information carries a boxed warning for hearing impairment, including permanent hearing loss. Some patients who had normal hearing before treatment developed hearing loss.
A healthcare professional experienced in lumbar punctures administers the medicine into the fluid around the spinal cord every two weeks. This requires appointments for treatment and hearing assessments.
The label calls for a comprehensive hearing evaluation before starting treatment and repeated evaluations during treatment. Those results guide dosage decisions. It also warns about problems with balance and coordination, called ataxia, and fatigue; severe cases requiring hospitalization have occurred.
The hearing concern predates this approval. In a 2017 NIH-led early-stage study, researchers reported additional hearing loss after treatment with the experimental compound, then called VTS-270. Those early findings concerned neurological progression, while Tuesday's approval rests on the later survival analysis.
Finding a treatment site
Beren's family support program assigns an access manager to help families identify a treatment site and coordinate insurance coverage, travel logistics and other practical arrangements.
The company says full out-of-pocket assistance is available to eligible families. That offer depends on program eligibility. Beren also has a caregiver program connecting families considering treatment with caregivers who have experience with it.
Families can contact Lembaz Family Support at 1-844-237-3600 to discuss access and treatment-site arrangements.





